Down 57%, Is AbCellera Biologics a Buy on the Dip? [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses might seem surprising if you've been paying attention to Wall Street analysts who follow AbCellera Biologics. KeyBanc has an overweight rating on the stock and a $7 per share price target, which implies a 103% gain over recent prices. Benchmark has a $9 per share price target on the stock, which implies a 161% gain. At times like these, it's important to remember that sell-side analysts have incentives to produce attention-getting price targets, but nothing to lose if things don't work out. Repairing the damage that following an underbaked investing thesis can cause to your retirement plans isn't as simple. Why AbCellera Biologics stock is down Biotech start-ups typically pour all their limited resources into the development of their single best candidate. AbCellera was founded on the idea that it could be an indispensable partner for drugmakers large and small by rapidl
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver [Yahoo! Finance]Yahoo! Finance
- AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024Business Wire
- We're Not Very Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024Business Wire
- Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71 [Yahoo! Finance]Yahoo! Finance
ABCL
Earnings
- 5/7/24 - Beat
ABCL
Sec Filings
- 6/24/24 - Form 4
- 6/24/24 - Form 4
- 6/24/24 - Form 4
- ABCL's page on the SEC website